Literature DB >> 9377576

Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.

M H Dreyling1, L Bullinger, G Ott, S Stilgenbauer, H K Müller-Hermelink, M Bentz, W Hiddemann, H Döhner.   

Abstract

Mantle cell lymphoma (MCL) has recently become generally accepted as a subentity of malignant lymphomas that is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in the overexpression of cyclin D1. Cyclin D1 forms a complex with cell cycle-dependent kinase (cdk) 4, which inactivates the retinoblastoma protein (pRB) via phosphorylation. However, in transgenic mice, the overexpression of cyclin D1 alone is not sufficient for the development of malignant lymphoma. To determine whether other members of the pRB pathway contribute to the malignant transformation of MCL, we analyzed 37 cases of MCL that were well characterized by morphology, immunophenotype, and/or interphase cytogenetics [detection of t(11;14)(q13;q32)]. Interphase fluorescence in situ hybridization was performed using a cosmid contig (250 kb) of the CDKN2/p16 region (encoding an inhibitor of the cyclin D1/cdk4 complex) and a phage contig (200 kb) of the Rb region. CDKN2/p16 deletion was detected in 15 cases (41%), including 6 homozygous deletions; Rb was deleted in 15 cases (41%), all of which were hemizygous deletions. Nine cases (24%) had deletions of both CDKN2/p16 and Rb. Further analysis of a subset of 17 MCLs revealed a highly significant correlation between CDKN2/p16 deletion and proliferation index, determined by the rate of Ki67 expression (P = 0.014; t test). No significant correlation was found between CDKN2/p16 deletion and the blastoid variant of MCL (P = 0.23; Fisher's test) or between proliferation index and blastoid morphology (P = 0.51; t test). Deletion of Rb did not have any impact on cell proliferation in addition to CDKN2/p16 deletion (P = 0.76; t test). Additional analysis of 13q14 deletions suggests that these deletions may target another gene telomeric to Rb. We conclude that deletion of CDKN2/p16 occurs in approximately one-half of MCLs and is a more relevant indicator of the proliferative features as compared to morphological criteria. In contrast, although deletions of chromosomal band 13q14 are frequent in MCL, inactivation of Rb seems not to be involved in the pathogenesis of MCL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377576

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 3.  Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Authors:  Adalgisa Condoluci; Davide Rossi; Emanuele Zucca; Franco Cavalli
Journal:  Curr Oncol Rep       Date:  2018-08-22       Impact factor: 5.075

4.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

5.  Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Authors:  Valentina Restelli; Monica Lupi; Micaela Vagni; Rosaria Chilà; Francesco Bertoni; Giovanna Damia; Laura Carrassa
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

6.  Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Authors:  Elahe A Mostaghel; Paul S Martin; Stephen Mongovin; Shani Frayo; Ailin Zhang; Kerstin L Edlefsen; Oliver W Press; Ajay K Gopal
Journal:  Exp Hematol       Date:  2017-01-21       Impact factor: 3.084

Review 7.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 8.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

9.  MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

Authors:  Yoko Tabe; Denise Sebasigari; Linhua Jin; Martina Rudelius; Theresa Davies-Hill; Kazunori Miyake; Takashi Miida; Stefania Pittaluga; Mark Raffeld
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

10.  Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival.

Authors:  Antonio Martinez; Beatriz Bellosillo; Francesc Bosch; Ana Ferrer; Silvia Marcé; Neus Villamor; German Ott; Emili Montserrat; Elias Campo; Dolors Colomer
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.